Zydus Lifesciences Limited
ZYDUSLIFE.NS
₹1174.20
▲ 2.11%
Zydus Lifesciences climbed 2.11% to ₹1174.20, holding close to its 52-week high of ₹1181.50 touched back on July 8, even as its June-quarter numbers showed a mixed picture — consolidated revenue grew a healthy 21.95% YoY to Rs 8,017 crore, but net profit slumped 35.93% to Rs 939.8 crore as EBITDA margins contracted sharply by 770 basis points to 24.1%. Despite the margin pressure, brokerages have stayed constructive on the stock, with Jefferies raising its target to Rs 1,200 from Rs 1,100 while maintaining a "Buy" call, and Prabhudas Lilladher sticking with an "Accumulate" rating and the same Rs 1,200 target. The stock has delivered a strong 18.79% return over the past year, though its two-year CAGR of just 2.65% points to a choppier medium-term journey. With 30 analysts tracking the counter and an average target of ₹1195.78 — barely above current levels — the street's consensus view stands at "hold."
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| 21.52% | 2.21% | 16.63% | 12.05% |
Analyst Consensus
Average Target Price: ₹1195.78 (range ₹800.00 - ₹1457.48) based on 30 analysts
Strong Buy: 7
Buy: 8
Hold: 8
Sell: 3
Strong Sell: 4
Related News
| Aug 11, 2026 | Zydus Lifesciences Q1 Consol Net Profit 9.4 Billion Rupees |
No comments:
Post a Comment